Busch Matthew C. 4

4 · AMGEN INC · Filed May 7, 2026

AI-generated summary of this filing

Updated May 8, 2026

Amgen (AMGN) VP Matthew Busch Receives Awards; 50 Shares Withheld

What Happened

Matthew C. Busch, Vice President, Finance & Chief Accounting Officer of Amgen, received equity awards on 2026-05-05: a derivative award of 2,969 units (grant value reported at $329.59 each, total ~$978,553) and an additional 455 shares recorded at $0.00 (see footnotes). On 2026-05-06, 50 shares were disposed/withheld at $329.59 per share to cover tax liability (total $16,480). These awards are compensation grants, not open-market purchases or sales.

Key Details

Transaction dates/prices:
- 2026-05-05: Award/acquisition — 2,969 derivative units @ $329.59 (total $978,553)
- 2026-05-05: Award/acquisition — 455 shares @ $0.00 (includes dividend equivalents)
- 2026-05-06: Tax withholding/payment — 50 shares @ $329.59 (disposed) = $16,480
Shares owned after the transaction: not stated in the filing.
Footnotes from the filing:
- F1: The RSUs vest in four equal annual installments (25% per year), commencing 5/5/2027; vested RSUs are paid one-for-one in common stock.
- F2: The 455 shares include 45 Dividend Equivalents credited to unvested RSUs and paid out according to the vesting schedule (with cash for any fractional shares).
- F3: The 2,969 derivative units correspond to non‑qualified stock options that vest/exercise in four equal annual installments beginning 5/5/2027.
Filing timeliness: Report filed 2026-05-07 for transactions on 2026-05-05–05-06 (appears timely).

Context

These entries are company compensation awards (RSUs and stock options) and a routine tax-withholding disposition — not an open-market sale indicating a change in conviction.
The derivative grant (options) is subject to multi-year vesting and is not immediately exercisable or sold; RSU and dividend-equivalent shares vest over time per the schedule in the footnotes.

Form 4

Period: 2026-05-05

VP, Finance & CAO

Transactions

Award
Common Stock
[F1]
2026-05-05+455→ 4,435 total
Tax Payment
Common Stock
[F2]
2026-05-06$329.59/sh−50$16,480→ 4,385 total
Award
Nqso (Right to Buy)
[F3]
2026-05-05$329.59/sh+2,969$978,553→ 2,969 total
Exercise: $329.59From: 2027-05-05Exp: 2036-05-05→ Common Stock (2,969 underlying)

Footnotes (3)

[F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
[F2]These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
[F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Signature

/s/ Matthew C. Busch|2026-05-07

1 file